Integrin Β5 Contributes to the Tumorigenic Potential of Breast Cancer Cells Through the SRC-Fak and MEK-ERK Signaling Pathways

Oncogene - United Kingdom
doi 10.1038/onc.2012.320
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

An EGFR/Src-dependent Β4 Integrin/Fak Complex Contributes to Malignancy of Breast Cancer

Scientific Reports
Multidisciplinary
2015English

Allergen‑removed Rhus�verniciflua Stokes Suppresses Invasion and Migration of Pancreatic Cancer Cells Through Downregulation of the JAK/STAT and SRC/Fak Signaling Pathways

Oncology Reports
MedicineCancer ResearchOncology
2018English

Helicobacter Pylori CagA Upregulation of CIP2A Is Dependent on the SRC and MEK/ERK Pathways

Journal of Medical Microbiology
MedicineMicrobiology
2009English

Cinnamomum Cassia Extracts Suppress Human Lung Cancer Cells Invasion by Reducing U-Pa/MMP Expression Through the FAK to ERK Pathways

International Journal of Medical Sciences
Medicine
2018English

DOK7V1 Influences the Malignant Phenotype of Lung Cancer Cells Through PI3K/AKT/mTOR and FAK/paxillin Signaling Pathways

International Journal of Oncology
Cancer ResearchOncology
2018English

[Corrigendum] Netrin‑1 Induces the Proliferation of Gastric Cancer Cells via the ERK/MAPK Signaling Pathway and FAK Activation

Oncology Reports
MedicineCancer ResearchOncology
2018English

Downregulation of CKS1B Restrains the Proliferation, Migration, Invasion and Angiogenesis of Retinoblastoma Cells Through the MEK/ERK Signaling Pathway

International Journal of Molecular Medicine
MedicineGenetics
2019English

MicroRNA 9-3p Targets 1 Integrin to Sensitize Claudin-Low Breast Cancer Cells to MEK Inhibition

Molecular and Cellular Biology
Cell BiologyMolecular Biology
2013English

Integrin-Fak Signaling Rapidly and Potently Promotes Mitochondrial Function Through STAT3

Cell Communication and Signaling
BiochemistryCell BiologyMolecular Biology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy